Erythromycin and Aranesp drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Erythromycin (erythromycin) and Aranesp (darbepoetin alfa). Common drug interactions include anaemia among females and anaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Erythromycin and Aranesp. It is created by eHealthMe based on reports of 42 people who take the same drugs from the FDA, and is updated regularly.

What is Erythromycin?

Erythromycin has active ingredients of erythromycin. It is often used in acne. eHealthMe is studying from 12,563 Erythromycin users. Check the latest studies of Erythromycin.

What is Aranesp?

Aranesp has active ingredients of darbepoetin alfa. It is often used in anemia. eHealthMe is studying from 54,331 Aranesp users. Check the latest studies of Aranesp.



On Jul, 06, 2026

42 people who take Erythromycin and Aranesp together, and have interactions are studied.

Erythromycin and Aranesp drug interactions.

What are the common drug interactions of Erythromycin and Aranesp, by gender? *:

female:

  1. Anaemia (lack of blood)
  2. Drug rash with eosinophilia and systemic symptoms (adverse drug reactions with rash)
  3. Stillbirth (a birth of dead foetus)
  4. Abdominal pain
  5. Renal failure acute (rapid kidney dysfunction)
  6. Back pain
  7. Arthralgia (joint pain)
  8. Confusional state
  9. Constipation
  10. Diarrhoea

male:

  1. Anaemia (lack of blood)
  2. Neutropenia (an abnormally low number of neutrophils)
  3. Hyperglycaemia (high blood sugar)
  4. Hyperlipidaemia (presence of excess lipids in the blood)
  5. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  6. Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)
  7. Swelling face
  8. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
  9. Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
  10. Aortic aneurysm (enlargement of an aortic artery caused by a weakening of the artery wall)

What are the common drug interactions of Erythromycin and Aranesp, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Blood creatine phosphokinase increased
  2. Blood lactate dehydrogenase increased
  3. Catatonia (unresponsive to external stimuli)
  4. Cough
  5. Drug level increased
  6. Pneumonia
  7. Pyrexia (fever)
  8. Renal impairment (severely reduced kidney function)
  9. Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)

30-39:

  1. Faecal occult blood positive
  2. Foetal death (death of foetus)
  3. Maternal exposure during pregnancy (use of substance during pregnancy)
  4. Stillbirth (a birth of dead foetus)
  5. Intra-uterine death
  6. Rouleaux formation (when red blood cells stack on to each other due to an abnormal shape)
  7. Staphylococcal infection (an infection with staphylococcus bacteria)
  8. Therapeutic response decreased (less preventive response)
  9. Abdominal pain
  10. Abdominal pain upper

40-49:

  1. Anaemia (lack of blood)
  2. Asthma
  3. Blood glucose decreased
  4. Depression
  5. Drug hypersensitivity
  6. Dyspnoea (difficult or laboured respiration)
  7. Hypertension (high blood pressure)
  8. Nausea (feeling of having an urge to vomit)
  9. Anaphylactic reaction (serious allergic reaction)
  10. Anxiety

50-59:

  1. Aphthous stomatitis (mouth ulcer)
  2. Arteriosclerosis (thickening and hardening of arteries)
  3. Asthma
  4. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  5. Atrioventricular block first degree (heart block first degree)
  6. Back pain
  7. Blood creatine phosphokinase increased
  8. Blood creatine phosphokinase mb increased
  9. Blood glucose fluctuation
  10. Blood phosphorus decreased

60+:

  1. Anaemia (lack of blood)
  2. Back pain
  3. Alopecia (absence of hair from areas of the body)
  4. Arthralgia (joint pain)
  5. Atrioventricular block (heart block)
  6. Atrioventricular block first degree (heart block first degree)
  7. Balance disorder
  8. Cardiac arrest
  9. Cardiac failure congestive
  10. Carotid artery aneurysm (a bulging or ballooning in the wall of a blood vessel)

What are the existing conditions these people have? *

  1. Chronic Renal Failure (kidney failure): 4 people, 9.52%
  2. Pain: 3 people, 7.14%
  3. Nausea (feeling of having an urge to vomit): 3 people, 7.14%
  4. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 7.14%
  5. Candidiasis (candidiasis or thrush is a fungal infection): 3 people, 7.14%
  6. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Erythromycin and Aranesp?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Erythromycin and Aranesp:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Erythromycin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Aranesp:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Erythromycin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Aranesp and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on erythromycin and darbepoetin alfa (the active ingredients of Erythromycin and Aranesp, respectively), and Erythromycin and Aranesp (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: